Amgen Inc. Revenues
Amgen Inc. (AMGN) reported Revenues of $6.53 billion for the 3-month period ending 2021-06-30, per its 10-Q filed 2021-08-04.
Discontinued › Income Statement › Revenue
us-gaap:Revenues · last filed 2021-08-04
- Amgen Inc. revenues for the quarter ending 2021-06-30 was $6.53B, a 5.16% increase year-over-year.
- Amgen Inc. revenues for the quarter ending 2021-03-31 was $5.90B, a 4.22% decline year-over-year.
- Amgen Inc. revenues for the quarter ending 2020-12-31 was $6.63B, a 7.05% increase year-over-year.
- Amgen Inc. revenues for the quarter ending 2020-09-30 was $6.42B, a 11.96% increase year-over-year.
- Amgen Inc. revenues for fiscal 2020 was $25.42B, a 8.83% increase from fiscal 2019.
- Amgen Inc. revenues for fiscal 2019 was $23.36B, a 1.62% decline from fiscal 2018.
- Amgen Inc. revenues for fiscal 2018 was $23.75B, a 3.93% increase from fiscal 2017.
- Amgen Inc. revenues for fiscal 2017 was $22.85B, a 0.62% decline from fiscal 2016.
| Period end | Revenues 3 month | Revenues 6 month | Revenues 9 month | Revenues 12 month |
|---|---|---|---|---|
| 2021-06-30 | $6.53B 10-Q · filed 2021-08-04 | $12.43B 10-Q · filed 2021-08-04 | $19.06B derived: sum of 3 quarters · filed 2021-08-04 | $25.48B derived: sum of 4 quarters · filed 2021-08-04 |
| 2021-03-31 | $5.90B 10-Q · filed 2021-04-28 | $12.54B derived: sum of 2 quarters · filed 2021-04-28 | $18.96B derived: sum of 3 quarters · filed 2021-04-28 | $25.16B derived: sum of 4 quarters · filed 2021-08-04 |
| 2020-12-31 | $6.63B derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-09 | $13.06B derived: sum of 2 quarters · filed 2021-02-09 | $19.26B derived: sum of 3 quarters · filed 2021-08-04 | $25.42B 10-K · filed 2021-02-09 |
| 2020-09-30 | $6.42B 10-Q · filed 2020-10-29 | $12.63B derived: sum of 2 quarters · filed 2021-08-04 | $18.79B 10-Q · filed 2020-10-29 | $24.99B derived: sum of 4 quarters · filed 2021-08-04 |
| 2020-06-30 | $6.21B 10-Q · filed 2021-08-04 | $12.37B 10-Q · filed 2021-08-04 | $18.56B derived: sum of 3 quarters · filed 2021-08-04 | $24.30B derived: sum of 4 quarters · filed 2021-08-04 |
| 2020-03-31 | $6.16B 10-Q · filed 2021-04-28 | $12.36B derived: sum of 2 quarters · filed 2021-04-28 | $18.09B derived: sum of 3 quarters · filed 2021-04-28 | $23.97B derived: sum of 4 quarters · filed 2021-04-28 |
| 2019-12-31 | $6.20B derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-09 | $11.93B derived: sum of 2 quarters · filed 2021-02-09 | $17.80B derived: sum of 3 quarters · filed 2021-02-09 | $23.36B 10-K · filed 2021-02-09 |
| 2019-09-30 | $5.74B 10-Q · filed 2020-10-29 | $11.61B derived: sum of 2 quarters · filed 2020-10-29 | $17.16B 10-Q · filed 2020-10-29 | $23.39B derived: sum of 4 quarters · filed 2021-02-09 |
| 2019-06-30 | $5.87B 10-Q · filed 2020-07-29 | $11.43B 10-Q · filed 2020-07-29 | $17.66B derived: sum of 3 quarters · filed 2021-02-09 | $23.56B derived: sum of 4 quarters · filed 2021-02-09 |
| 2019-03-31 | $5.56B 10-Q · filed 2020-05-01 | $11.79B derived: sum of 2 quarters · filed 2021-02-09 | $17.69B derived: sum of 3 quarters · filed 2021-02-09 | $23.75B derived: sum of 4 quarters · filed 2021-02-09 |
| 2018-12-31 | $6.23B derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-09 | $12.13B derived: sum of 2 quarters · filed 2021-02-09 | $18.19B derived: sum of 3 quarters · filed 2021-02-09 | $23.75B 10-K · filed 2021-02-09 |
| 2018-09-30 | $5.90B 10-Q · filed 2019-10-30 | $11.96B derived: sum of 2 quarters · filed 2019-10-30 | $17.52B 10-Q · filed 2019-10-30 | $23.32B derived: sum of 4 quarters · filed 2020-02-12 |
| 2018-06-30 | $6.06B 10-Q · filed 2019-07-31 | $11.61B 10-Q · filed 2019-07-31 | $17.41B derived: sum of 3 quarters · filed 2020-02-12 | $23.19B derived: sum of 4 quarters · filed 2020-02-12 |
| 2018-03-31 | $5.55B 10-Q · filed 2019-05-01 | $11.36B derived: sum of 2 quarters · filed 2020-02-12 | $17.13B derived: sum of 3 quarters · filed 2020-02-12 | $22.94B derived: sum of 4 quarters · filed 2020-02-12 |
| 2017-12-31 | $5.80B derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-12 | $11.57B derived: sum of 2 quarters · filed 2020-02-12 | $17.39B derived: sum of 3 quarters · filed 2020-02-12 | $22.85B 10-K · filed 2020-02-12 |
| 2017-09-30 | $5.77B 10-Q · filed 2018-10-31 | $11.58B derived: sum of 2 quarters · filed 2018-10-31 | $17.05B 10-Q · filed 2018-10-31 | $23.01B derived: sum of 4 quarters · filed 2019-02-13 |
| 2017-06-30 | $5.81B 10-Q · filed 2018-07-27 | $11.27B 10-Q · filed 2018-07-27 | $17.24B derived: sum of 3 quarters · filed 2019-02-13 | $23.05B derived: sum of 4 quarters · filed 2019-02-13 |
| 2017-03-31 | $5.46B 10-Q · filed 2018-04-25 | $11.43B derived: sum of 2 quarters · filed 2019-02-13 | $17.24B derived: sum of 3 quarters · filed 2019-02-13 | $22.93B derived: sum of 4 quarters · filed 2019-02-13 |
| 2016-12-31 | $5.96B derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-13 | $11.78B derived: sum of 2 quarters · filed 2019-02-13 | $17.46B derived: sum of 3 quarters · filed 2019-02-13 | $22.99B 10-K · filed 2019-02-13 |
| 2016-09-30 | $5.81B 10-Q · filed 2017-10-26 | $11.50B derived: sum of 2 quarters · filed 2017-10-26 | $17.03B 10-Q · filed 2017-10-26 | $22.56B derived: sum of 4 quarters · filed 2018-02-13 |
| 2016-06-30 | $5.69B 10-Q · filed 2017-07-26 | $11.21B 10-Q · filed 2017-07-26 | $16.75B derived: sum of 3 quarters · filed 2018-02-13 | $22.47B derived: sum of 4 quarters · filed 2018-02-13 |
| 2016-03-31 | $5.53B 10-Q · filed 2017-04-27 | $11.06B derived: sum of 2 quarters · filed 2018-02-13 | $16.79B derived: sum of 3 quarters · filed 2018-02-13 | $22.16B derived: sum of 4 quarters · filed 2018-02-13 |
| 2015-12-31 | $5.54B derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-13 | $11.26B derived: sum of 2 quarters · filed 2018-02-13 | $16.63B derived: sum of 3 quarters · filed 2018-02-13 | $21.66B 10-K · filed 2018-02-13 |
| 2015-09-30 | $5.72B 10-Q · filed 2016-10-28 | $11.09B derived: sum of 2 quarters · filed 2016-10-28 | $16.13B 10-Q · filed 2016-10-28 | $21.46B derived: sum of 4 quarters · filed 2017-02-14 |
| 2015-06-30 | $5.37B 10-Q · filed 2016-07-29 | $10.40B 10-Q · filed 2016-07-29 | $15.73B derived: sum of 3 quarters · filed 2017-02-14 | $20.77B derived: sum of 4 quarters · filed 2017-02-14 |
| 2015-03-31 | $5.03B 10-Q · filed 2016-05-02 | $10.36B derived: sum of 2 quarters · filed 2017-02-14 | $15.39B derived: sum of 3 quarters · filed 2017-02-14 | $20.57B derived: sum of 4 quarters · filed 2017-02-14 |
| 2014-12-31 | $5.33B derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-14 | $10.36B derived: sum of 2 quarters · filed 2017-02-14 | $15.54B derived: sum of 3 quarters · filed 2017-02-14 | $20.06B 10-K · filed 2017-02-14 |
| 2014-09-30 | $5.03B 10-Q · filed 2015-11-02 | $10.21B derived: sum of 2 quarters · filed 2015-11-02 | $14.73B 10-Q · filed 2015-11-02 | $19.74B derived: sum of 4 quarters · filed 2016-10-31 |
| 2014-06-30 | $5.18B 10-Q · filed 2015-08-05 | $9.70B 10-Q · filed 2015-08-05 | $14.71B derived: sum of 3 quarters · filed 2016-10-31 | $19.46B derived: sum of 4 quarters · filed 2016-10-31 |
| 2014-03-31 | $4.52B 10-Q · filed 2015-04-27 | $9.53B derived: sum of 2 quarters · filed 2016-10-31 | $14.28B derived: sum of 3 quarters · filed 2016-10-31 | $18.96B derived: sum of 4 quarters · filed 2016-10-31 |
| 2013-12-31 | $5.01B derived: 8-K 12 month − 10-Q 9 month · filed 2016-10-31 | $9.76B derived: sum of 2 quarters · filed 2016-10-31 | $14.44B derived: sum of 3 quarters · filed 2016-10-31 | $18.68B 8-K · filed 2016-10-31 |
| 2013-09-30 | $4.75B 10-Q · filed 2014-10-29 | $9.43B derived: sum of 2 quarters · filed 2014-10-29 | $13.66B 10-Q · filed 2014-10-29 | $18.09B derived: sum of 4 quarters · filed 2015-02-19 |
| 2013-06-30 | $4.68B 10-Q · filed 2014-08-05 | $8.92B 10-Q · filed 2014-08-05 | $13.34B derived: sum of 3 quarters · filed 2015-02-19 | $17.66B derived: sum of 4 quarters · filed 2015-02-19 |
| 2013-03-31 | $4.24B 10-Q · filed 2014-04-30 | $8.66B derived: sum of 2 quarters · filed 2015-02-19 | $12.98B derived: sum of 3 quarters · filed 2015-02-19 | $17.45B derived: sum of 4 quarters · filed 2015-02-19 |
| 2012-12-31 | $4.42B derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-19 | $8.74B derived: sum of 2 quarters · filed 2015-02-19 | $13.22B derived: sum of 3 quarters · filed 2015-02-19 | $17.27B 10-K · filed 2015-02-19 |
| 2012-09-30 | $4.32B 10-Q · filed 2013-10-29 | $8.80B derived: sum of 2 quarters · filed 2013-10-29 | $12.84B 10-Q · filed 2013-10-29 | $16.82B derived: sum of 4 quarters · filed 2014-02-24 |
| 2012-06-30 | $4.48B 10-Q · filed 2013-08-06 | $8.53B 10-Q · filed 2013-08-06 | $12.50B derived: sum of 3 quarters · filed 2014-02-24 | $16.44B derived: sum of 4 quarters · filed 2014-02-24 |
| 2012-03-31 | $4.05B 10-Q · filed 2013-05-03 | $8.02B derived: sum of 2 quarters · filed 2014-02-24 | $11.96B derived: sum of 3 quarters · filed 2014-02-24 | $15.92B derived: sum of 4 quarters · filed 2014-02-24 |
| 2011-12-31 | $3.97B derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-24 | $7.92B derived: sum of 2 quarters · filed 2014-02-24 | $11.88B derived: sum of 3 quarters · filed 2014-02-24 | $15.58B 10-K · filed 2014-02-24 |
| 2011-09-30 | $3.94B 10-Q · filed 2012-11-06 | $7.90B derived: sum of 2 quarters · filed 2012-11-06 | $11.61B 10-Q · filed 2012-11-06 | $15.45B derived: sum of 4 quarters · filed 2013-02-27 |
| 2011-06-30 | $3.96B 10-Q · filed 2012-08-08 | $7.67B 10-Q · filed 2012-08-08 | $11.51B derived: sum of 3 quarters · filed 2013-02-27 | $15.32B derived: sum of 4 quarters · filed 2013-02-27 |
| 2011-03-31 | $3.71B 10-Q · filed 2012-05-08 | $7.55B derived: sum of 2 quarters · filed 2013-02-27 | $11.36B derived: sum of 3 quarters · filed 2013-02-27 | $15.17B derived: sum of 4 quarters · filed 2013-02-27 |
| 2010-12-31 | $3.84B derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-27 | $7.66B derived: sum of 2 quarters · filed 2013-02-27 | $11.46B derived: sum of 3 quarters · filed 2013-02-27 | $15.05B 10-K · filed 2013-02-27 |
| 2010-09-30 | $3.82B 10-Q · filed 2011-11-04 | $7.62B derived: sum of 2 quarters · filed 2011-11-04 | $11.21B 10-Q · filed 2011-11-04 | $15.02B derived: sum of 4 quarters · filed 2012-02-29 |
| 2010-06-30 | $3.80B 10-Q · filed 2011-08-08 | $7.40B 10-Q · filed 2011-08-08 | $11.21B derived: sum of 3 quarters · filed 2012-02-29 | $15.02B derived: sum of 4 quarters · filed 2012-02-29 |
| 2010-03-31 | $3.59B 10-Q · filed 2011-05-10 | $7.40B derived: sum of 2 quarters · filed 2012-02-29 | $11.21B derived: sum of 3 quarters · filed 2012-02-29 | $14.93B derived: sum of 4 quarters · filed 2012-02-29 |
| 2009-12-31 | $3.81B derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-29 | $7.62B derived: sum of 2 quarters · filed 2012-02-29 | $11.33B derived: sum of 3 quarters · filed 2012-02-29 | $14.64B 10-K · filed 2012-02-29 |
| 2009-09-30 | $3.81B 10-Q · filed 2010-11-08 | $7.53B derived: sum of 2 quarters · filed 2010-11-08 | $10.83B 10-Q · filed 2010-11-08 | $14.58B derived: sum of 4 quarters · filed 2011-02-25 |
| 2009-06-30 | $3.71B 10-Q · filed 2010-08-09 | $7.02B 10-Q · filed 2010-08-09 | $10.77B derived: sum of 3 quarters · filed 2011-02-25 | $14.65B derived: sum of 4 quarters · filed 2011-02-25 |
| 2009-03-31 | $3.31B 10-Q · filed 2010-05-07 | $7.06B derived: sum of 2 quarters · filed 2011-02-25 | $10.93B derived: sum of 3 quarters · filed 2011-02-25 | $14.70B derived: sum of 4 quarters · filed 2011-02-25 |
| 2008-12-31 | $3.75B derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-25 | $7.63B derived: sum of 2 quarters · filed 2011-02-25 | $11.39B derived: sum of 3 quarters · filed 2011-02-25 | $15.00B 10-K · filed 2011-02-25 |
| 2008-09-30 | $3.88B 10-Q · filed 2009-11-06 | $7.64B derived: sum of 2 quarters · filed 2009-11-06 | $11.25B 10-Q · filed 2009-11-06 | |
| 2008-06-30 | $3.76B 10-Q · filed 2009-08-10 | $7.38B 10-Q · filed 2009-08-10 | ||
| 2007-12-31 | $14.77B 10-K · filed 2010-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GILEAD SCIENCES, INC. (GILD) | United States | $185.522B | -48.37 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |